PDK2 and Alzheimer disease: Furthermore, the novel anti‐AD candidate COR enhances both glycolysis and OXPHOS to rescue abnormal metabolic reprogramming by targeting HKII and PDK2, inducing a shift in microglial phenotype from an M1 to M2‐dominant phenotype and ultimately promoting neuron survival (Figure 8).